1.0 Ag/kg body wt human corticotropin-releasing factor (hCRF) and 0.005 IU/kg body wt lysine vasopressin (LVP) were administered in a bolus dose to patients receiving daily or alternate-day glucocorticoid therapy. In normal subjects with this hCRF-LVP test, the plasma ACTH increment was significantly greater (-2.5-fold) 15 min after injection than under the CRF test. In patients receiving daily glucocorticoid therapy (> 15 mg prednisolone or an equivalent daily dose), the plasma ACTH and cortisol responses to hCRF-LVP were suppressed 2 wk to 1 mo after the beginning of glucocorticoid administration but partially improved at 2-10 mo, and was markedly suppressed several years later. On the other hand, in patients receiving alternate-day glucocorticoid therapy, the plasma ACJ7H response was normal at 2 wk, normal or higher at 1-3 mo, and normal after 4 mo. A normal plasma cortisol response was observed throughout the test period in patients receiving alternate-day therapy after pulse therapy, whereas plasma cortisol response was gradually improved in patients receiving alternate-day therapy after several months of daily therapy.
Introduction
Since Vale and his co-workers (1, 2) reported on the sequence analysis and synthesis of ovine and rat hypothalamic corticotropin-releasing factor (CRF)' and Shibahara et al. (3) showed that the structure ofhuman CRF (hCRF) was the same as that of rat CRF, the ovine CRF-and hCRF-stimulating tests have been used to examine pituitary-adrenal function in various clinical disorders (4) (5) (6) . We observed that hCRF alone did not produce sufficient pituitary-adrenocortical response in some normal subjects. In vivo (7) and in vitro (8) studies have shown that vasopressin acts synergistically with CRF to release ACTH from the anterior pituitary. Therefore, we developed a hCRF-lysine vasopressin (LVP) test in which a low dose of LVP was added to hCRF. Here, we examined the responsiveness of this test on the pituitary-adrenocortical axis of patients receiving daily or alternate-day glucocorticoid therapy. Subjects 15, 30, 60, 90 , and 120 min after injection for the plasma ACTH and cortisol assays.
Hormone assays. Plasma ACTH and cortisol were measured by RIA using the ACTH-RIA kit (CEA-IRE-Sorin, Gif-sur-Yvette, France) and Sectionary processed antibody coating cortisol-RIA kit (Dai-ichi Radioisotope Lab, Tokyo, Japan), respectively. Analysis of data. In normal subjects, the responses from the hCRF-LVP test were compared with those from the hCRF test. Increments from the baseline to the peak and the areas under the response curve (above the basal value) calculated by trapezoidal integration were used as parameters for comparisons. Patients receiving glucocorticoid therapy daily were separated into three groups according to the ACTH response patterns, namely, 2 wk to I mo, 2-10 mo, and several years. Patients receiving alternate-day glucocorticoid therapy were separated into four groups, namely, 2 wk, 1 mo, 2-3 mo, and 4-13 mo.
Responses on the hCRF-LVP test from normal subjects were compared with those from patients receiving daily and alternate-day therapy. Basal levels and increments of plasma ACTH and cortisol were compared with those of normal subjects. The statistical analysis was conducted by t test.
Results
Normal subjects. In normal subjects, mean plasma ACTH showed a peak at 30 min and plasma cortisol at 60 min in response to hCRF (Fig. 1) . Neither Table II ). There was a slight negative correlation between the total dose ofglucocorticoid and the plasma cortisol increments (P < 0.05). Alternate-day glucocorticoid therapy. In patients receiving alternate-day glucocorticoid therapy after pulse therapy, mean plasma ACTH increment was normal at 2 wk, higher at 1 mo, and normal again after 2 mo, whereas mean plasma cortisol increment was normal throughout the treatment period. Basal ACTH levels were low within 3 mo but were normal after 4 mo (Fig. 3, Table II ). In alternate-day therapy after long-term daily therapy plasma ACTH response recovered to normal levels, whereas plasma cortisol response remained lowered at 2 wk after starting alternate-day therapy. In these cases at 1-2 mo, the response of plasma ACTH was higher than in normal subjects, whereas plasma cortisol remained lowered. However, the responsiveness of plasma ACTH and cortisol were almost normal after 4 mo (Fig. 3) . sponse was observed in the exogenous ACTH-stimulating test in all patients receiving > 15 mg prednisolone daily (16) . It is difficult to compare directly the responses of plasma ACTH and cortisol in patients receiving daily therapy vs. patients receiving alternate-day therapy, as the tests were done at different times after the last glucocorticoid administration (24 vs. 48 h). Another purpose of this investigation, however, was to estimate the pituitary-adrenocortical responsiveness in these groups in their most recovered conditions after the last glucocorticoid administration and before the next glucocorticoid administration. Using this test, we could at least compare optimal pituitary-adrenocortical responsiveness in these two groups at the periods when the tests were performed on their steroid therapy.
Discussion
The severe suppression of the pituitary-adrenocortical response 2 wk to 1 mo after the beginning of steroid administration in patients receiving daily therapy may be ascribed to the negative feedback effect of the very high dose of prednisolone in the beginning (12) (13) (14) (15) . A gradual decrease in the doses of prednisolone in the therapeutic regimen may have caused the partial improvement in response at 2-10 mo. Glucocorticoid administration for several years seemed to cause a persistent suppression in corticotrophs and an atrophy of the adrenal cortex.
The hyperresponse of the pituitary gland to hCRF-LVP in two patients receiving alternate-day therapy for 2 wk to 2 mo might be explained by the up-regulation of CRF receptors on corticotrophs due to a reduction in endogenous CRF and an increase in the releasable pool of ACTH in recovered corticotrophs. It was revealed that the reserve function of ACTH and cortisol release was well-maintained in patients receiving alternate-day glucocorticoid therapy, especially in patients receiving therapy after steroid pulse therapy. ACTH release recovered earlier than cortisol release in patients receiving alternate-day therapy after long-term daily therapy. Alternate-day therapy thus had the advantage of causing little suppression of 
